InflaRx Announces First Patient Dosed in Phase 2a Study for Oral C5aR Inhibitor INF904 JENA, Germany, Dec. 20, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today...

InflaRx Hosts R&D Event Highlighting the Promise of INF904 Thought leaders in complement inhibition, chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) provide compelling new insights into the strong development rationales, potential...

SLRN NOTICE: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages ACELYRIN, INC. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SLRN NEW YORK, Nov. 24, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ACELYRIN, INC. (NYSE: SLRN) between May 4, 2023 and September...